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Introduction {#sec001}
============

Seasonal influenza virus infections cause 290,000--650,000 deaths annually and severe morbidity in 3--5 million people \[[@ppat.1008714.ref001]\]. Currently licensed vaccines induce strain-specific antibodies but fail to induce influenza-specific CD8^+^ T cell responses \[[@ppat.1008714.ref002]\]. Furthermore, current vaccines provide little or no protection in the face of a pandemic, caused by the emergence of new influenza A virus (IAV) subtypes, as observed in the most recent 2009 pandemic-H1N1 outbreak \[[@ppat.1008714.ref003]\]. Therefore, in the absence of cross-protective neutralizing antibodies, an efficient way to counteract a novel influenza strain is by re-calling pre-existing, cross-strain-protective cytotoxic CD8^+^ T cells \[[@ppat.1008714.ref004]--[@ppat.1008714.ref006]\].

Protection from influenza-specific memory CD8^+^ T cells is directed towards more conserved internal viral proteins, such as matrix protein 1 (M1) and nucleoprotein \[[@ppat.1008714.ref007]--[@ppat.1008714.ref009]\]. Thus, memory CD8^+^ T cell responses generated by seasonal IAV infection can provide broader cross-protection against subsequent challenges from distinct influenza virus strains and subtypes, also called heterosubtypic immunity \[[@ppat.1008714.ref004], [@ppat.1008714.ref005], [@ppat.1008714.ref010], [@ppat.1008714.ref011]\]. In humans, CD8^+^ T cell cross-reactivity between pandemic H1N1-2009 and H3N2 \[[@ppat.1008714.ref012]\], and between the two pandemics H1N1-2009 and H1N1-1918 \[[@ppat.1008714.ref010]\], led to a robust re-call of pre-existing CD8^+^ T cell immunity towards the newly emerging avian H7N9-2013 strain \[[@ppat.1008714.ref005], [@ppat.1008714.ref013]\], providing evidence for pre-existing heterosubtypic immunity \[[@ppat.1008714.ref014]\]. Our recent studies also revealed that influenza-specific CD8^+^ T cells can provide unprecedented immunity across all influenza A, B and C viruses capable of infecting humans \[[@ppat.1008714.ref015]\], and similarly across influenza A \[[@ppat.1008714.ref016], [@ppat.1008714.ref017]\] and influenza B viruses \[[@ppat.1008714.ref015]\]. These studies demonstrate that pre-existing CD8^+^ T cell immunity could reduce disease severity, decrease viral burden, ameliorate morbidity and mortality, leading to a rapid recovery of the host. Thus, cross-strain protective CD8^+^ T cell-based vaccines could provide life-saving therapeutic strategies for novel reassorting influenza strains with pandemic potential.

During viral infection, CD8^+^ T cells recognize viral peptides, typically 8--10 amino acids long, that are presented on HLA class I (HLA-I) molecules on the surface of virally-infected cells \[[@ppat.1008714.ref018]\]. Some peptides are highly antigenic and stimulate high magnitude CD8^+^ T cell responses, termed "immunodominant", while others elicit "subdominant" responses. Thus, overall CD8^+^ T cell responses directed against multiple immunogenic peptides give rise to immunodominance hierarchy patterns. Immunodominance hierarchies can be affected by several factors, including naïve precursor frequencies, CD8^+^ T cell receptor (TCR) repertoires capable of generating primary and memory CD8^+^ T cells, killing capacity, effector polyfunctionality, and TCR avidity for peptide-HLA complexes \[[@ppat.1008714.ref019]--[@ppat.1008714.ref021]\]. These factors are further complicated by HLA polymorphisms observed in the human population \[[@ppat.1008714.ref020]\].

CD8^+^ T cell immunodominance hierarchies in humans has been previously characterized in HIV \[[@ppat.1008714.ref022]\] and CMV \[[@ppat.1008714.ref023]\]. However, immunodominance hierarchies in the context of IAV infection across different HLAs are less clear. In 104 HIV-1-infected patients, CD8^+^ T cell responses towards otherwise known immunodominant HIV-I-derived peptides presented on HLA-A1, -A2, -A3 and -A24, were reduced in the presence of HLA-B27 and HLA-B57 CD8^+^ T cell responses, indicating immunodomination of HLA-B27/B57 over other HLA types during HIV-1 infection \[[@ppat.1008714.ref022]\]. Their protective role in delaying disease progression towards AIDS during HIV-1 infection has also been documented \[[@ppat.1008714.ref024]--[@ppat.1008714.ref026]\]. To understand factors governing immunodominance patterns in IAV, immunodominance hierarchies need to be defined for known immunodominant IAV epitopes, followed by investigation of the determinants of CD8^+^ T cell immunodominance across different HLAs.

HLA-A\*02:01 is the most prevalent allele found across multiple ethnicities worldwide, including Caucasians (25%), Mexican Seri (54%) and Native North Americans (22%) \[[@ppat.1008714.ref005], [@ppat.1008714.ref017], [@ppat.1008714.ref027]\]. Considered to be the most immunodominant IAV epitope is the HLA-A\*02:01-restricted M1~58-66~ epitope (hereafter A2/M1~58~), which is universally conserved within influenza viruses circulating over the last century \[[@ppat.1008714.ref017]\]. We have previously defined 5 other universal IAV epitopes presented by common HLA class I types (HLA-A\*03:01-NP~265-273~, -B\*27:05-NP~383-391~, -B\*57:01-NP~199-207~, -B\*18:01-NP~219-226~ and -B\*08:01-NP~225-233~) \[[@ppat.1008714.ref005]\], of which to date, there have been no extensive studies examining their CD8^+^ T cell immunodominance hierarchies.

Here, we investigated immunodominant A2/M1~58~ responses in heterozygote individuals expressing the other universal HLAs for IAVs. We analyzed T cell polyfunctionality, proliferation kinetics, peptide/HLA-I avidity and direct *ex vivo* TCRαβ repertoire to determine how these factors are impacted by HLA-A\*02:01 responses in the presence of different HLA-I molecules.

Results {#sec002}
=======

A2/M1~58~^+^CD8^+^ T cell immunodominance hierarchy is altered by HLA-B\*27:05 expression {#sec003}
-----------------------------------------------------------------------------------------

To define the immunodominance hierarchy across universal influenza CD8^+^ T cell epitopes (HLA-A\*02:01-M1~58-66~, HLA-A\*03:01-NP~265-273~, HLA-B\*27:05-NP~383-391~, HLA-B\*57:01-NP~199-207~, HLA-B\*18:01-NP~219-226~ and HLA-B\*08:01-NP~225-233~) \[[@ppat.1008714.ref005]\] within an individual, IAV-specific CD8^+^ T cell responses towards those epitopes were measured in healthy blood donors following peptide stimulation and IFN-γ/TNF cytokine production ([Fig 1A](#ppat.1008714.g001){ref-type="fig"}). Robust IFN-γ^+^CD8^+^ T cell responses were readily detected across all 6 conserved epitopes: A2/M1~58~ (mean = 9.4%, range = 0.1--31.6%), A3/NP~265~ (8.3%, 0.1--24.1%), B8/NP~225~ (3.0%, 0.1--7.2%), B18/NP~219~ (13.1%, 7.0--15.9%), B27/NP~383~ (16.7%, 4.5--41.1%) and B57/NP~199~ (9.98%, 7.3%-14.6%), confirming the immunogenicity of these highly conserved epitopes ([Fig 1B](#ppat.1008714.g001){ref-type="fig"}).

![Reduced magnitude of A2/M158+CD8^+^ T cell responses in HLA-A2^+^/B27^+^ individuals.\
(**A**) Representative FACS plots of cytokine production following IFN-γ/TNF ICS assay of day 10 peptide-expanded T cell lines from healthy PBMCs for each universal epitope. (**B**) Frequency of IFN-γ-producing CD8^+^ T cells from T cell lines expanded: A2/M1~58~ (n = 20), A3/NP~265~ (n = 9), B8/NP~225~ (n = 6), B18/NP~219~ (n = 4), B27/NP~383~ (n = 7) and B57/NP~199~ (n = 3). Bars represent mean±SEM. (**C**) Heatmap of relative contribution of IFN-γ^+^CD8^+^ T cell responses across different epitopes restricted by different HLAs in individuals with more than 1 universal HLA allele (n = 20). NA represents the individual who is either homozygote or has a non-universal HLA at that locus. (**D**) Representative FACS plots comparing A2/M1~58~^+^CD8^+^ T cell responses in HLA-A2^+^/non-B27 individuals versus A2/M1~58~ and B27/NP~383~ responses in HLA-A2^+^/B27^+^ individuals. Day 10 A2/M1~58~ and B27/NP~383~ responses in HLA-A2^+^/B27^+^ individuals after T cell lines were generated in parallel with (**E**) single peptide-pulsed or (**F**) live PR8 virus-pulsed cells before performing ICS with relevant peptide. Data (mean±SEM) are pooled from blood (open circle) and spleen (open square) donors over 2--3 independent experiments (n = 5--8). Exact *p*-values are shown (Mann-Whitney t test).](ppat.1008714.g001){#ppat.1008714.g001}

The immunodominance patterns in donors co-expressing 2 or more of the universal HLAs were subsequently assessed in human blood and spleen. When we compared the magnitude of IFN-γ^+^CD8^+^ T cell responses directed at the most studied immunodominant IAV epitope A2/M1~58~ \[[@ppat.1008714.ref005], [@ppat.1008714.ref017]\] against other universal epitope responses within the same individual, our analyses revealed that A2/M1~58~^+^CD8^+^ T cell responses were immunodominant over HLAs A3, B8 and B18, but this was strikingly not the case in donors that co-expressed B27 or B57 ([Fig 1C](#ppat.1008714.g001){ref-type="fig"}). As HLA-B\*27:05 mediates protection in HIV and HCV \[[@ppat.1008714.ref028]\], and is associated with viral escape mutations in HIV \[[@ppat.1008714.ref029]\] and a slow accumulation of variants within IAV-H3N2 \[[@ppat.1008714.ref030]\], we focused on understanding the immunodominance mechanisms of B27/NP~383~^+^CD8^+^ T cell responses over A2/M1~58~^+^ responses in HLA-A2^+^/B27^+^ co-expressed individuals. Although A2/M1~58~^+^ responses were immunodominant in non-HLA-B27 donors, individuals co-expressing HLA-A2^+^/B27^+^ showed significantly higher IFN-γ^+^CD8^+^ T cell responses towards B27/NP~383~ (mean = 9.6%, SD±3.2%) in comparison to subdominant A2/M1~58~ responses (3.5%±1.2%) across all the blood and spleen donors tested ([Fig 1D and 1E](#ppat.1008714.g001){ref-type="fig"}, *p* = 0.03).

To determine whether the B27/NP~383~\>A2/M1~58~ immunodominance hierarchy also occurred during influenza virus infection, we measured CD8^+^ T cell responses in blood and spleen following stimulation with autologous IAV-infected APCs ([Fig 1F](#ppat.1008714.g001){ref-type="fig"}), rather than peptide-pulsed APCs ([Fig 1E](#ppat.1008714.g001){ref-type="fig"}), which more closely resembles the natural antigen presentation pathway \[[@ppat.1008714.ref020]\]. Stimulation of PBMCs with virus-infected APCs, followed by a 6-hr ICS verified significantly higher B27/NP~383~^+^CD8^+^ T cell responses (3.8%±1.2%) than A2/M1~58~^+^ responses (0.89%±0.9%) ([Fig 1F](#ppat.1008714.g001){ref-type="fig"}, *p* = 0.02). Taken together, our data show, that the expression of specific HLAs (like HLA-B\*27:05) can lead to immunodomination and markedly reduce immunodominance of universal influenza-specific CD8^+^ T cells.

Reduced *ex vivo* frequencies within subdominant A2/M1~58~^+^CD8^+^ T cells in A2^+^B27^+^ donors {#sec004}
-------------------------------------------------------------------------------------------------

As the experiments presented in [Fig 1](#ppat.1008714.g001){ref-type="fig"} were performed using *in vitro* assays, we subsequently determined the frequencies of immunodominant and subdominant influenza-specific CD8^+^ T cells directly *ex vivo* using a dual tetramer-associated magnetic enrichment (TAME) ([Fig 2A](#ppat.1008714.g002){ref-type="fig"}), allowing increased detection of epitope-specific T cells by up to 100-fold \[[@ppat.1008714.ref031]--[@ppat.1008714.ref033]\]. In accordance with our *in vitro* experiments, subdominant A2/M1~58~^+^CD8^+^ T cell frequencies in HLA-A2^+^/B27^+^ donors were significantly diminished within both PBMCs (4.9E-05±2.0E-05, *p* = 0.019) and spleen (8.9E-06±3.0E-06, *p* = 0.042), compared to dominant A2/M1~58~^+^CD8^+^ T cells (PBMCs: 2.8E-04±9.4E-05; spleen: 4.6E-05 ± 4.7E-06) ([Fig 2B](#ppat.1008714.g002){ref-type="fig"}). The frequencies of immunodominant B27/NP~383~^+^CD8^+^ T cells were trending higher than the subdominant A2/M1~58~^+^CD8^+^ T cells in both PBMC and spleen co-expressed donors.

![Ex vivo frequencies and T cell phenotype of A2/M158+ and B27/NP383+ CD8^+^ T cells.\
(**A**) Representative FACS plots of TAME-enriched A2/M1~58~^+^ and B27/NP~383~^+^ CD8^+^ T cells isolated from PBMC and spleen of HLA-A2^+^/B27^+^ individuals. Minimal cells were observed in the flow through fractions. Cells were gated on live CD14^-^CD19^-^CD3^+^CD8^+^ T cells. (**B**) Precursor frequencies of A2/M1~58~^+^ and B27/NP~383~^+^ CD8^+^ T cells from HLA-A2^+^/B27^+^ (PBMC n = 13; spleen n = 6) versus A2/M1~58~^+^CD8^+^ T cells from HLA-A2^+^/non-B27 donors (PBMC n = 10; spleen n = 5). (**C**) CCR7 and CD45RA expression profiles of TAME-enriched tetramer^+^ cells overlaid on top of total CD8^+^ T cells from each group with at least 10 tetramer^+^ events. (**D**) Frequencies of naïve (T~N~, CCR7^+^CD45RA^+^), central memory (T~CM~, CCR7^+^CD45RA^-^), effector memory (T~EM~, CCR7^-^CD45RA^-^) and effector (T~EFF,~ CCR7^-^CD45RA^+^) T cell populations for immunodominant A2/M1~58~^+^ (black, n = 4), subdominant A2/M1~58~^+^ (maroon, n = 11) and immunodominant B27/NP~383~^+^ (green, n = 12) specificities. Data are pooled from blood and spleen donors over 4--5 independent experiments. (**B** and **D**) Bars show mean±SEM and statistically significant exact *p*-values are shown (*p*\<0.05, Kruskal-Wallis test, one-way ANOVA).](ppat.1008714.g002){#ppat.1008714.g002}

Phenotypic *ex vivo* analyses of immunodominant and subdominant influenza-specific A2/M1~58~^+^CD8^*+*^ T cells involved CCR7 and CD45RA expression to characterize naïve (T~N~, CCR7^+^CD45RA^+^), central memory (T~CM~, CCR7^+^CD45RA^-^), effector memory (T~EM~, CCR7^-^CD45RA^-^) and effector (T~EFF,~ CCR7^-^CD45RA^+^) T cells ([Fig 2C](#ppat.1008714.g002){ref-type="fig"}). The memory populations were relatively similar between immunodominant and subdominant A2/M1~58~^+^CD8^+^ T cells. However, immunodominant B27/NP~383~^+^CD8^+^ T cells were significantly enriched for effector cells and with diminished central memory phenotype in comparison to both immunodominant and subdominant A2/M1~58~^+^CD8^+^ T cells, which were predominantly of central memory rather than effector phenotype ([Fig 2D](#ppat.1008714.g002){ref-type="fig"}), suggesting different transitioning between B27/NP~383~^+^CD8^+^ and A2/M1~58~^+^CD8^+^ T cell memory subsets.

Distinct A2/M1~58~^+^CD8^+^ TCRαβ repertoires in the presence of HLA-B\*27:05 {#sec005}
-----------------------------------------------------------------------------

Altered *ex vivo* frequencies and phenotypes of A2/M1~58~^+^CD8^+^ T cells in A2/B27-expressing donors suggested possible underlying differences in TCRαβ repertoire composition and diversity between immunodominant and subdominant A2/M1~58~^+^CD8^+^ T cells. To dissect TCRαβ repertoires, we single-cell isolated TAME-enriched subdominant A2/M1~58~^+^CD8^+^ T cells directly *ex vivo* from three HLA-A2^+^/B27^+^ donors for TCR analyses and compared them to our previously defined immunodominant A2/M1~58~^+^ TCRαβ repertoires from HLA-A2^+^/non-HLA-B27 donors \[[@ppat.1008714.ref017]\], which predominantly consisted of the TRBV19 and TRAV27 gene segments and the prominent public TRBV19/TRAV27 TCRαβ clonotype: CDR3α-GGSQGNL and CDR3β-SSIRSYEQ \[[@ppat.1008714.ref017]\].

Notably, dissection of TRBV and TRAV gene usage revealed that subdominant A2/M1~58~^+^CD8^+^ T cells did not predominantly consist of the public TRBV19 and TRAV27 gene segments but encompassed a diverse array of TRBV and TRAV genes, with one donor (SD1) displaying neither TRBV19 nor TRAV27 ([Fig 3A](#ppat.1008714.g003){ref-type="fig"}, [Table 1](#ppat.1008714.t001){ref-type="table"}). In fact, the public A2/M1~58~^+^ TRBV19/TRAV27 clonotype was only present in two HLA-A2^+^/B27^+^ donors at low frequencies (SD2 20% and SD3 10.2%) ([Fig 3B and 3C](#ppat.1008714.g003){ref-type="fig"}), compared to high public TCRαβ clonotype frequencies observed in all HLA-A2^+^/non-HLA-B27 donors (average 48%, range 15--67%), as previously described \[[@ppat.1008714.ref017]\]. Moreover, TRBV19 and, more significantly TRAV27 gene usage, were lower in the subdominant A2/M1~58~^+^ TCRαβ repertoires compared to the known immunodominant repertoires (TRAV27: *p* = 0.02) ([Fig 3B](#ppat.1008714.g003){ref-type="fig"}).

![Subdominant A2/M158+ TCRαβ repertoire display reduction in A2/M1~58-~specific "public motif".\
(**A**) Pie charts of TRAV and TRBV usage within subdominant A2/M1~58~^+^CD8^+^ T cells in three HLA-A2^+^/B27^+^ blood donors. Public TRBV19 and TRAV27 motifs are represented by blue and green shades respectively. (**B**) Frequencies of the dominant A2/M1~58-~specific gene usage are shown for paired TRBV19/TRAV27 or TRBV19 and TRAV27 groups for our three subdominant HLA-A2^+^/B27^+^ donors (SD1-3, open circles) versus previously reported immunodominant HLA-A2^+^/non-B27 donors (closed circles) \[[@ppat.1008714.ref017]\]. Mean±SEM are shown. (**C**) Circos plots made in RStudio v.1.2.1335 of paired TCRαβ clonotypes from SD1-3 donors. (**D**) Frequencies of CDR3β and CDR3α aa lengths are shown for 3 our subdominant donors SD1-3.](ppat.1008714.g003){#ppat.1008714.g003}
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###### TCRαβ repertoire within subdominant A2/M158+CD8^+^ T cells.

![](ppat.1008714.t001){#ppat.1008714.t001g}

  TRBV                   TRBJ          CDR3β                          CDR3α             TRAV              TRAJ         SD1      SD2      SD3
  ---------------------- ------------- ------------------------------ ----------------- ----------------- ------------ -------- -------- ---------
  TRBV19                 TRBJ2-1       SSILAGAYNEQ                    ND                TRAV19            TRAJ22                5         
  TRBV19                 TRBJ2-7       SSIRSAYEQ                      GAHGSSNTGKL       TRAV27            TRAJ37                5         
  **TRBV19**             **TRBJ2-3**   **SSI**[**RS**]{.ul}**SDTQ**   **GAGGGSQGNL**    **TRAV27**        **TRAJ42**            **5**     
  **TRBV19**             **TRBJ2-7**   **SSI**[**RS**]{.ul}**SYEQ**   **GGGSGGSQGNL**   **TRAV27**        **TRAJ42**            **5**     
  **TRBV19**             **TRBJ2-7**   **SSI**[**RS**]{.ul}**SYEQ**   **GGGSQGNL**      **TRAV27**        **TRAJ42**            **10**    
  TRBV19                 TRBJ2-1       SSLAGPYNEQ                     FMTATFTSGTYKY     TRAV38-1          TRAJ40                5         
  TRBV19                 TRBJ1-1       SSPQGGAEA                      GQIXXRAGXXL       TRAV35            TRAJ5                 5         
  TRBV19                 TRBJ2-1       SSP[RS]{.ul}ALEQ               VNWGGGSQGNL       TRAV12-2          TRAJ42                15        
  TRBV9                  TRBJ1-5       SSPWDRGQPQ                     VEXXXXKI          TRAV1-2           TRAJ30                5         
  TRBV19                 TRBJ1-4       SSV[RS]{.ul}DEKL               GNYGGSQGNL        TRAV25            TRAJ42                15        
  TRBV24-1               TRBJ1-6       TSIAPI                         APPNSGNTPL        TRAV29/DV5        TRAJ29                10        
  TRBV15                 TRBJ2-7       TSKSGGPYEQ                     PKGYSTL           TRAV21            TRAJ11                5         
  TRBV15                 TRBJ1-1       TSRDLGVWTEA                    VKGPYGGGSQGNL     TRAV8-1           TRAJ42                5         
  TRBV30                 TRBJ2-3       ND                             GIPSTGANSKL       TRAV35            TRAJ56                5         
  TRBV28                 TRBJ2-7       SSVFGTSYEQ                     LPSCSGNTPL        TRAV16            TRAJ29       45                 
  TRBV28                 TRBJ2-7       SSVFGTSYEQ                     LPSCSGNTPL        TRAV16            TRAJ15       7                  
  TRBV28                 TRBJ2-7       SSVFGTSYEQ                     VSNQAGTAL         TRAV3             TRAJ15       17                 
  TRBV28                 TRBJ2-7       SSVFGTSYEQ                     C\#\#NQAGTAL      TRAV3             TRAJ15       3                  
  TRBV27                 TRBJ1-1       SSYGQGLEA                      APNDYKL           TRAV8-2/TRAV8-4   TRAJ37       14                 
  TRBV27                 TRBJ1-1       SSYGQGLEA                      AXAT\#GKL         TRAV13-2          TRAJ37       3                  
  TRBV27                 TRBJ1-1       SSYGQGLEA                      AXATXAX\#         TRAV13-2          TRAJ37       11                 
  **TRBV19**             **TRBJ2-7**   **SI**[**RS**]{.ul}**SYEQ**    **GSGGSQGNL**     **TRAV27**        **TRAJ42**                     **3.4**
  TRBV19                 TRBJ2-3       GTGSIDTQ                       RDGTGANNL         TRAV3             TRAJ36                         3.4
  TRBV19                 TRBJ1-2       SFGSYGY                        RATSGGSNYKL       TRAV16            TRAJ53                         3.4
  TRBV19                 TRBJ2-7       SI[RS]{.ul}SYEQ                ND                TRAV8-3           TRAJ44                         3.4
  TRBV19                 TRBJ2-2       SA[RS]{.ul}TGEL                EPKG\#TGANNL      TRAV36/DV7        TRAJ36                         3.4
  TRBV9                  TRBJ1-5       SVEGNQPQ                       REYMGSSYKL        TRAV14/DV4        TRAJ12                         3.4
  TRBV19                 TRBJ2-2       SA[RS]{.ul}TGEL                NYGGSQGNL         TRAV25            TRAJ42                         6.9
  TRBV30                 TRBJ2-3       SVAGGPGDTQ                     VPMEYGNKL         TRAV21            TRAJ47                         3.4
  TRBV19                 TRBJ2-2       SA[RS]{.ul}TGEL                ND                TRAV36/DV7        TRAJ42                         3.4
  TRBV19                 TRBJ1-5       SLFSQQPQ                       VYGGSQGNL         TRAV27            TRAJ42                         3.4
  TRBV19                 TRBJ2-2       SV[RS]{.ul}TGEL                GSGGSQGNL         TRAV27            TRAJ42                         3.4
  **TRBV19**             **TRBJ1-1**   **SI**[**RS**]{.ul}**SYEA**    **NYGGSQGNL**     **TRAV27**        **TRAJ42**                     **3.4**
  TRBV19                 TRBJ2-1       ST[RS]{.ul}GDEQ                WNQGGKL           TRAV8-6           TRAJ23                         3.4
  TRBV23-1               TRBJ2-2       NA                             RDGTGANNL         TRAV3             TRAJ36                         3.4
  TRBV19                 TRBJ2-2       SA[RS]{.ul}TGEL                ND                TRAV36/DV7        TRAJ42                         3.4
  **TRBV19**             **TRBJ2-7**   **SI**[**RS**]{.ul}**SYEQ**    **GGSQGNL**       **TRAV27**        **TRAJ42**                     **3.4**
  TRBV9                  TRBJ2-2       ND                             NYGGSQGNL         TRAV25            TRAJ42                         3.4
  TRBV19                 TRBJ2-2       ST[RS]{.ul}TGEL                NYGGSQGNL         TRAV25            TRAJ42                         3.4
  TRBV19                 TRBJ2-4       DEGSGIQ                        ND                TRAV27            TRAJ31                         3.4
  TRBV19                 TRBJ2-3       SSI[RS]{.ul}TDTQ               CNYGGSQGNL        TRAV25            TRAJ42                         6.9
  TRBV19                 TRBJ1-2       SSTGSYGY                       AFMINAGGTSYGKLT   TRAV38-1          TRAJ52                         13.8
  TRBV19                 TRBJ2-7       SSV[RS]{.ul}AYEQ               GAIGSSNTGKL       TRAV27            TRAJ37                         10.3
  **No. of sequences**                                                                  **30**            **20**       **29**            

Bold = public TCR, underlined = public "RS" CDR3β motif, ND = not determined, X = undefined aa sequence, \# = out-of-frame sequence resulting in unproductive pair. SD = donor code.

Further analysis of a CDR3 length usage ([Fig 3D](#ppat.1008714.g003){ref-type="fig"}) demonstrated a minor difference in the preferred CDR3β-chain length (8 aa) between immunodominant (87%±9%) \[[@ppat.1008714.ref017]\] and subdominant A2/M1~58~^+^CD8^+^ T cells (51%±20.6%, SD2 preferred 9 aa length). Strikingly, subdominant A2/M1~58~^+^CD8^+^ T cells had a preference for a longer CDR3α length of 9 aa (41.6%±13.2%), as compared to a shorter 7 aa length preference in immunodominant donors (48.8%±34.7%) \[[@ppat.1008714.ref017]\].

Structural studies have defined the CDR3β motif "RS" as an essential feature for the "peg-notch" recognition by the public TRBV19/TRAV27 TCR of the "plain vanilla" A2/M1~58~ epitope \[[@ppat.1008714.ref034]\]. Subdominant A2/M1~58~^+^CD8^+^ T cells had a considerable reduction in the CDR3β "RS" motif ([Table 1](#ppat.1008714.t001){ref-type="table"}, 56.5%±2.19%, 18/43 unique TCRs across 2 donors, 1 donor had no "RS" motif) in comparison to immunodominant A2/M1~58~^+^CD8^+^ T cells (82.3%±15.9%, 20/33 unique TCRs across 3 donors) \[[@ppat.1008714.ref017]\]. Furthermore, the Simpson's Diversity Index (values 0 to 1, with 1 being the most diverse) for subdominant A2/M1~58~^+^CD8^+^ TCRs (0.9±0.1) was on average \~25% more diverse that immunodominant A2/M1~58~^+^CD8^+^ TCRs (0.7±0.3).

Overall, the influenza-specific A2/M1~58~^+^CD8^+^ TCRαβ repertoire revealed striking differences in TCRαβ clonal composition and diversity between subdominant (in HLA-B\*27:05-expressing donors) and immunodominant (in non-HLA-B\*27:05 individuals) A2/M1~58~^+^CD8^+^ T cells, including reduced TRAV27 and TRBV19 "RS" motif usage, lower occurrence of the public TRBV19/TRAV27 clonotype, increased diversity and increased prevalence of private clonotypes. These differences in TCRαβ repertoires between A2/B27- and A2/non-B27-expressing donors can, at least in part, explain differential immunodominance patterns of influenza-responding CD8^+^ T cells directed at the A2/M1~58~ epitope.

Diminished polyfunctional capacity of subdominant A2/M1~58~^+^ CD8^+^ T cells {#sec006}
-----------------------------------------------------------------------------

Having found altered immunodominance hierarchy of A2/M1~58~^+^CD8^+^ T cells in the presence of HLA-B\*27:05 expression, associated with strikingly different TCRαβ repertoires, we subsequently assessed the consequence of such changes on the quality and functionality of A2/M1~58~^+^CD8^+^ T cell responses in both HLA-A2^+^/non-B27 and HLA-A2^+^/B27^+^ individuals. We defined their ability to simultaneously produce multiple cytokines, defined as polyfunctionality \[[@ppat.1008714.ref035]\], such as IFN-γ, TNF and the degranulation/cytotoxicity marker CD107a ([Fig 4A](#ppat.1008714.g004){ref-type="fig"}). A2/M1~58~^+^CD8^+^ T cells displayed significantly reduced functional profiles (\~45% \>1 functional response) when compared to B27/NP~383~^+^CD8^+^ T cells (\~78%) in HLA-A2^+^/B27^+^ individuals ([Fig 4B](#ppat.1008714.g004){ref-type="fig"}, *p* = 0.0002), which also had strikingly higher frequencies of triple cytokine producers. ([Fig 4C](#ppat.1008714.g004){ref-type="fig"}, *p* = 0.003). Similarly, these subdominant A2/M1~58~^+^CD8^+^ T cells had significantly reduced polyfunctionality compared to the those in HLA-A2^+^/non-B27 donors (\~64%) ([Fig 4B](#ppat.1008714.g004){ref-type="fig"}, *p* = 0.007), and a trend towards a reduction in triple cytokine producers ([Fig 4C](#ppat.1008714.g004){ref-type="fig"}). Interestingly, the total CD107a^+^A2/M1~58~^+^ response remained unchanged between the groups ([Fig 4B](#ppat.1008714.g004){ref-type="fig"}, magenta arc), suggesting that A2/M1~58~^+^CD8^+^ T cells maintain degranulation capacity independent of HLA-B27 co-expression. Expression of effector molecules, granzyme B and perforin, were also measured, both \~80% expressed.

![Diminished polyfunctionality of A2/M158+CD8^+^ T cells in HLA-A2^+^/B27^+^ individuals.\
(**A**) Representative FACS plots of CD107a, IFN-γ and TNF responses of day 10 peptide-expanded CD8^+^ T cell lines from HLA-A2^+^/non-B27 and HLA-A2^+^/B27^+^ donors. (**B**) Pie charts representing the average fractions of expanded CD8^+^ T cells expressing different combinations of CD107a, IFN-γ and TNF were generated using Pestle v1.8 and SPICE v5.35 software. Arcs represent average frequency of individual cytokines. Exact *p*-values are calculated using Spice permutation test (10,000) replicates. (**C**) Frequencies of the CD8^+^ T cell functional response producing different combinations of CD107a, IFN-γ and TNF. Data (mean±SEM) are pooled from blood and spleen donors over 2--3 independent experiments (n = 7--8). For each cytokine combination, statistically significant exact *p*-values are shown for each response (*p*\<0.05, Kruskal-Wallis test, one-way ANOVA).](ppat.1008714.g004){#ppat.1008714.g004}

Subdominant A2/M1~58~^+^ CD8^+^ T cells have lower functional T cell avidity {#sec007}
----------------------------------------------------------------------------

Antigen sensitivity is a major readout for CD8^+^ T cell functional avidity \[[@ppat.1008714.ref036]\]. To assess the functional avidity between immunodominant and subdominant influenza-specific CD8^+^ T cells, the level of antigen sensitivity was determined by re-stimulating T cell lines with 10-fold dilutions of peptide and measuring the EC~50~ of the total IFN-γ response ([Fig 5A](#ppat.1008714.g005){ref-type="fig"}). Our data showed that immunodominant B27/NP~383~^+^ and A2/M1~58~^+^ CD8^+^ T cells (mean EC~50~: 10^−10^ M and 10^−10^ M, respectively) were 10 times more sensitive to the peptide antigen stimulation compared to subdominant A2/M1~58~^+^ CD8^+^ T cells (mean EC50: 10^−9^ M) ([Fig 5B](#ppat.1008714.g005){ref-type="fig"}). However, the functional avidity EC~50~ values of subdominant A2/M1~58~^+^CD8^+^ T cells are just above the optimal nanomolar to picomolar physiological ranges \[[@ppat.1008714.ref037]\], suggesting that they could still mount an immune response, albeit at lower magnitudes. The differences in antigen sensitivity between immunodominant and subdominant CD8^+^ T cells of the same specificity can be explained, at least partially, by different TCRαβ clonotypes within these immunodominant and subdominant A2/M1~58~^+^CD8^+^ T cells, highlighting the basis for distinct patterns of immunodominance hierarchy.

![Reduced antigen sensitivity in subdominant A2/M158+CD8^+^ T cells.\
(**A**) Peptide titration curve and **(B)** EC~50~ values for each T cell specificity after 12 days of peptide expansion. Mean and SEM are shown (n = 3 for each group).](ppat.1008714.g005){#ppat.1008714.g005}

Reduced proliferative capacity within subdominant A2/M1~58~^+^ versus dominant B27/NP~383~^+^ CD8^+^ T cells {#sec008}
------------------------------------------------------------------------------------------------------------

To determine the effect of altered TCRαβ repertoires and pHLA-I avidity on the proliferative capacity of immunodominant B27/NP~383~^+^ and subdominant A2/M1~58~^+^CD8^+^ T cells, both A2/M1~58~^+^CD8^+^ T cells and B27/NP~383~^+^CD8^+^ T cells were stimulated with their cognate peptides, and their functional and proliferative kinetics were assessed via IFN-γ production and peptide/MHC-tetramer staining, respectively ([Fig 6A](#ppat.1008714.g006){ref-type="fig"}). In all 5 donors tested, the magnitude of proliferating B27/NP~383~^+^CD8^+^ T cells was greater than A2/M1~58~^+^CD8^+^ T cells, with higher frequencies of IFN-γ producers from day 6 onwards, which was significantly higher on days 9 and 12 ([Fig 6B](#ppat.1008714.g006){ref-type="fig"}, both *p* = 0.007). To verify the cytokine readout data, enumeration of A2/M1~58~^+^ and B27/NP~383~^+^ tetramer^+^CD8^+^ T cells showed more rapid expansion in the number of B27/NP~383~-tetramer^+^CD8^+^ T cells compared to A2/M1~58~-tetramer^+^CD8^+^ T cells from day 9 up to day 12 (average 2.6-fold increase) ([Fig 6C](#ppat.1008714.g006){ref-type="fig"}). Thus, B27/NP~383~^+^ CD8^+^ T cells immunodominance over A2/M1~58~^+^ CD8^+^ T cells was associated with higher proliferative capacity of B27/NP~383~^+^ CD8^+^ T cells in HLA-A\*02:01/HLA-B\*27:05-expressing individuals.

![Higher proliferative capacity of B27/NP383+CD8^+^ T cells over A2/M158+CD8^+^ T cells in HLA-A2^+^/B27^+^ individuals.\
(**A**) Representative kinetics of IFN-γ^+^ and tetramer^+^ responses of peptide-stimulated T cell lines on days 3, 6, 9 and 12 of culture. (**B**) Parallel IFN-γ^+^ A2/M1~58~^+^ and B27/NP~383~^+^ responses and (**C**) absolute numbers of tetramer^+^CD8^+^ T cells over time for each individual and as a group (mean±SEM). Blood donors: SD1-3; spleen donors: SD4-5. Statistically significant exact *p*-values are shown (Mann Whitney t test).](ppat.1008714.g006){#ppat.1008714.g006}

Taken together, our data demonstrate that the immunodominant or subdominant status of A2/M1~58~^+^CD8^+^ T cells and the underlying differences in TCRαβ repertoires can significantly affect influenza-specific CD8^+^ T cell polyfunctionality, quality, pMHC avidity and proliferative capacity of A2/M1~58~^+^ CD8^+^ T cells. While in HLA-A2^+^/non-B27 individuals, immunodominant A2/M1~58~^+^CD8^+^ T cells are highly abundant, polyfunctional and display high avidity and public TCRαβ repertoires, subdominant A2/M1~58~^+^CD8^+^ T cells in HLA-A2^+^/B27^+^ co-expressing individuals are of lower frequency, display lower polyfunctional, are less proliferative (compared to B27/NP~383~^+^ CD8^+^ T cells), with low avidity TCRαβ repertoires.

Discussion {#sec009}
==========

Our study reports, that immunodominance can occur within human prominent influenza-specific CD8^+^ T cells with co-expression of another specific HLA class I molecule. While broadly cross-reactive universal A2/M1~58~^+^CD8^+^ T cells are immunodominant, contain the optimal public TRBV19/TRAV27 TCRαβ repertoire and display highly polyfunctional and proliferative capacity in non-HLA-B\*27:05 individuals, A2/M1~58~^+^CD8^+^ T cells in HLA-B\*27:05-expressing donors are subdominant, with largely distinct TCRαβ clonotypes and markedly reduced proliferative and polyfunctional capacity. Differences in TCRαβ repertoires between immunodominant and subdominant A2/M1~58~^+^CD8^+^ T cell populations might explain differential quantitative and qualitative characteristics of these influenza-responding CD8^+^ T cells directed at the same A2/M1~58~^+^ epitope. Our data highlight the need to understand immunodominance hierarchies within individual donors across a spectrum of prominent virus-specific CD8^+^ T cell specificities prior to designing T cell-directed vaccines and immunotherapies.

T cell-based vaccination strategies inducing cross-reactive CD8^+^ T cell immunity have the potential to provide broad and long-lasting protection against distinct influenza A virus strains \[[@ppat.1008714.ref007], [@ppat.1008714.ref016], [@ppat.1008714.ref017], [@ppat.1008714.ref038]\], and even across all human influenza A, B and C viruses \[[@ppat.1008714.ref015]\], including unpredictable, newly emerging strains with a pandemic potential. Ideally, the vaccine should encompass highly immunogenic epitopes for a diverse population with different HLAs. A number of prominent and "universal" (directed at viral peptides conserved over the last century) CD8^+^ T cell specificities restricted by a range of HLA alleles have been identified \[[@ppat.1008714.ref005], [@ppat.1008714.ref014], [@ppat.1008714.ref039]--[@ppat.1008714.ref041]\], with A2/M1~58~ being the most immunodominant, widely studied and highly prevalent in the global population. However, it is largely unknown how virus-specific CD8^+^ T cell responses are elicited towards a vaccine cocktail of multiple universal influenza epitopes restricted by different HLAs, and whether one epitope induces immunodomination over others. Our study thus focused on understanding the immunodominance hierarchy for universal influenza-specific CD8^+^ T cell responses to provide insights towards a rational design of broadly-protective universal influenza vaccines.

Immunodominance hierarchy patterns were dissected across universal HLAs (HLA-A\*02:01, -A\*03:01, -B\*08:01, -B\*18:01, -B\*27:05 and -B\*57:01), which provide broad population coverage worldwide \[[@ppat.1008714.ref005]\]. Several studies have focused on HLA-A\*02:01-driven immune responses towards influenza virus infection \[[@ppat.1008714.ref017], [@ppat.1008714.ref032], [@ppat.1008714.ref042], [@ppat.1008714.ref043]\] directed towards the immunodominant A2/M1~58~ epitope \[[@ppat.1008714.ref041]\]. In context of other universal HLAs, A2/M1~58~^+^CD8^+^ T cell responses remained the most immunodominant over A3/B8/B18 epitopes but were greatly reduced in individuals co-expressing HLA-B\*27:05 or HLA-B\*57:01. One study by Boon *et al*. showed that IFN-γ^+^B27/NP~383~^+^ CD8^+^ T cell responses were significantly higher than A2/M1~58~^+^ responses, although *in vitro* virus-expanded A2/M1~58~^+^ CD8^+^ T cell responses were of the same magnitudes when compared to HLA-A2^+^/non-B27 donors \[[@ppat.1008714.ref044]\]. In our study, we found significant differences not only between B27/NP~383~^+^ CD8^+^ and A2/M1~58~^+^ CD8^+^ T cells in A2/B27 donors but also for A2/M1~58~^+^ CD8^+^ T cells between A2/B27 and A2/non-B27 donors *ex vivo* and *in vitro*.

HLA-B\*27:05 has been associated with superior immune control during HIV \[[@ppat.1008714.ref045], [@ppat.1008714.ref046]\] and HCV-1 \[[@ppat.1008714.ref047]\] infections. HLA-B\*27:05-restricted immune control was attributed to higher levels of polyfunctionality, functional avidity and proliferation within HIV-specific B27-KK10^+^CD8^+^ T cells \[[@ppat.1008714.ref048]\]. CD8^+^ T cells displaying higher polyfunctionality improved vaccine efficacy towards vaccinia virus and Leishmania major \[[@ppat.1008714.ref049]--[@ppat.1008714.ref051]\]. High proliferative capacity of epitope-specific CD8^+^ T cells was linked to better protection against HIV-1 infection \[[@ppat.1008714.ref052]\]. CD8^+^ T cells of high antigen sensitivity, thus increased functional avidity, could mediate effective viral clearance at low antigen concentrations \[[@ppat.1008714.ref053]--[@ppat.1008714.ref055]\]. Collectively, these studies provided key interdependent mechanisms for superior immune CD8^+^ T cell responses. Our study demonstrated that immunodominant B27/NP~383~^+^CD8^+^ T cells, in the context of influenza virus infection, were more superior to subdominant A2/M1~58~^+^CD8^+^ T cells by exhibiting higher polyfunctionality, increased proliferative capacity and higher antigen sensitivity within HLA-A2^+^/HLA-B27^+^ co-expressed individuals. In contrast, A2/M1~58~^+^CD8^+^ T cells in the absence of HLA-B27 were highly immunodominant displaying higher qualitative features that resemble the immunodominant B27/NP~383~^+^CD8^+^ T cell response.

Given the qualitative and quantitative differences observed between immunodominant and subdominant A2/M1~58~^+^CD8^+^ T cells, our *ex vivo* phenotypic analysis showed no differences in their T cell differentiation phenotype, which were mainly CCR7^+^CD45RA^-^ "central memory" T cells. Conversely, the immunodominant B27/NP~383~^+^CD8^+^ T cell population had significantly higher proportions of CCR7^-^CD45RA^+^ "effector" cells compared to both A2/M1~58~^+^CD8^+^ T cell populations, a phenotype that warrants further investigation as "effector" T cells were originally believed to be terminally differentiated and exhausted, but new evidence shows that effector T cells contribute to a pool of long-lived memory T cells \[[@ppat.1008714.ref056], [@ppat.1008714.ref057]\]. However, while HLA-A\*02:01^+^M1~58~^+^ and HLA-B\*27:05^+^NP~383~^+^ CD8^+^ T cells are of different phenotypes, they do not differ in terms of CD107a expression, a marker of T cell degranulation and thus cytotoxicity.

We showed that the superior features of immunodominant A2/M1~58~^+^CD8^+^ T cells compared to the subdominant CD8^+^ T cell responses, in terms of response magnitude, polyfunctionality, avidity, proliferative capacity and precursor frequency, could be linked to the differences in their TCRαβ repertoires in both gene signatures and TCR diversity. Immunodominant A2/M1~58~^+^CD8^+^ T cells predominantly consisted of the public TRAV27/TRBV19 TCR signature \[[@ppat.1008714.ref017]\], which was absent or reduced in subdominant A2/M1~58~^+^CD8^+^ T cells that displayed more diverse private repertoires and lower precursor frequencies. Similar features of subdominant A2/M1~58~^+^CD8^+^ T cells from this study were recently described by our group in our aging elderly cohort showing a loss in prominent public TCRs but expansion of private suboptimal TCR clonotypes, which was associated with lower precursor frequencies \[[@ppat.1008714.ref032], [@ppat.1008714.ref058]\]. Similarly, we have found that immunodominant A68/NP~145~^+^ CD8^+^ T cell responses were linked to highly expanded TCRαβ clonotypes, whereas subdominant responses in other individuals had more diverse non-expanded TCRαβ clonotypes \[[@ppat.1008714.ref038]\]. Our findings are reminiscent of the HLA-B\*08:01/B\*44:02 trans-allele EBV model that impacted on the public LC13-TCR response against the HLA-B\*08:01-restricted FLRGRAYGL epitope, which was found in most HLA-B\*08:01 donors, but was explicitly replaced with a subdominant CF34-TCR response in HLA-B\*08:01^+^/B\*44:02^+^ donors \[[@ppat.1008714.ref059], [@ppat.1008714.ref060]\].

Our findings have implications for current and future T cell-based vaccine candidates and how the vaccine responses are assessed to further advance into clinical stages. Particularly in HLA-A2^+^/B27^+^ individuals, total CD8^+^ T cell responses could be underestimated when measuring A2/M1~58~^+^CD8^+^ T cell responses alone. This can be exemplified by a challenge study with the Modified Vaccinia virus Ankara (MVA) vaccine antigen consisting of complete NP and M1 from A/Panama/2007/99 joined by a 7 aa linker sequence (MVA+NP+M1) \[[@ppat.1008714.ref061]\], where only A2/M1~58~-tetramer CD8^+^ T cell responses were measured \[[@ppat.1008714.ref062]\]. Similarly, only M1-specific CD8^+^ T cell responses, but not NP-specific responses, were assessed in tonsil MNCs following in vitro stimulation with the MVA-NP+M1 vaccine \[[@ppat.1008714.ref063]\]. Furthermore, a T cell-based vaccine candidate called Flu-v consists of 4 synthetic polypeptides, which includes the A2/M1~58~ epitope but not the B27/NP~383~ epitope \[[@ppat.1008714.ref064]\]. Our study highlights the importance of considering the whole spectrum of immunodominant epitopes, other than A2/M1~58~, in the design and assessment of vaccine-induced CD8^+^ T cell responses.

Overall, in the presence of HLA-B27, we demonstrate a strong immunodominance hierarchy pattern of B27/NP~383~^+^CD8^+^ T cell responses being far more superior than the A2/M1~58~^+^CD8^+^ T cell response. Functional, quantitative and phenotypic characteristics within immunodominant and subdominant A2/M1~58~^+^CD8^+^ T cells were underpinned by differential TCRαβ repertoires. These findings have implications in understanding and modulating antiviral and anticancer CD8^+^ T cell responses generated by therapeutic immunizations or vaccinations.

Methods {#sec010}
=======

Ethics statement {#sec011}
----------------

All experiments were conducted in accordance to the Australian National Health and Medical Research Council Code of Practice. Buffy coats (n = 30) were obtained from the Australian Red Cross Lifeblood. Peripheral bloods were obtained from healthy adults (n = 3) recruited at the University of Melbourne and Deepdene Medical Clinic, which were approved by the Human Research Ethics Committee (HREC) of the University of Melbourne (\#1443389.4). All participants provided written informed consent prior to inclusion in the study. Human spleens from deceased organ donors (n = 10) were obtained following next-of-kin consent via DonateLife Victoria and approved by the Australian Red Cross Lifeblood Blood Service Ethics Committee (\#2015\#08). Cryopreserved PBMCs (n = 10) were obtained from Erasmus Medical Centre, Netherlands (approved by the Sanquin Bloodbank after informed consent was obtained).

HLA typing and cell isolation {#sec012}
-----------------------------

HLA-typing was performed by VTIS at Australian Red Cross Lifeblood (West Melbourne, VIC). PBMCs were freshly isolated by Ficoll-Paque density-gradient centrifugation and cryopreserved. Mononuclear cells (MNCs) were isolated from spleens as previously described \[[@ppat.1008714.ref058]\]. The patient information is detailed in [Table 2](#ppat.1008714.t002){ref-type="table"}.

10.1371/journal.ppat.1008714.t002

###### List of donors used in the study.

![](ppat.1008714.t002){#ppat.1008714.t002g}

  Donor code    Age   HLA-A   HLA-B   Source               
  ------------- ----- ------- ------- ------------ ------- -------------
  D1            59    01:01   02:01   08:01        44:02   Buffy Pack
  D2            ND    01:01   02:01   08:01        35:01   Buffy Pack
  D3            53    01:01   02:01   08:01        27:05   Buffy Pack
  D4            ND    01:01   02:01   08:01        35:01   Buffy Pack
  D5            47    01:01   02:01   08:01        27:05   Buffy Pack
  D6            30    02:01   03:01   40:01 (60)   56:01   Buffy Pack
  D7            25    02:01   03:01   07:02        40:01   Buffy Pack
  D8            54    02:01   03:01   35:01        57:01   Buffy Pack
  D9            50    02:01   68:01   27:05        15:18   Buffy Pack
  D11           64    02:01   03:01   27:05        13:02   Buffy Pack
  D12/SD1       50    02:01   26:01   07:02        27:05   Buffy Pack
  D13           37    02:01   03:01   07:02        40:01   Buffy Pack
  D14           42    02:01   03:02   18:01        35:08   Whole Blood
  D15/SD3       25    02:01   24:02   27:05        35:01   Buffy Pack
  D18           56    02:01           07:02        57:01   Buffy Pack
  D19           58    02:01   24:02   27:05        35:01   Spleen
  D20           68    01:01   02:01   08:01        35:01   Buffy Pack
  D21/SD2       58    2       3       14           27      Whole Blood
  D22           49    03:01           07:02        27:05   Spleen
  D23           ND    01:01   02:01   08:01        27:05   Buffy Pack
  D24           47    02:01   11:01   44:02        51:01   Buffy Pack
  D25           51    01:01   02:01   07:02        44:02   Buffy Pack
  D26           33    02:01   33:03   07:02        27:02   Whole Blood
  D27           ND    01:01   02:01   08:01        35:01   Buffy Pack
  D28           ND    01:01   02:01   08:01        35:01   Buffy Pack
  D29           45    02:01           07:02        44:02   Buffy Pack
  D30           ND    01:01   02:01   08:01        27:05   Buffy Pack
  D31           ND    01:01   02:01   08:01        27:05   Buffy Pack
  D32           47    02:01   29:02   15:01        35:01   Buffy Pack
  D33           62    02:01           07:02        44:02   Buffy Pack
  D34           67    01:01   02:01   13:02        44:32   Buffy Pack
  D35           22    02:01   11:01   15:02        54:01   Buffy Pack
  D36           69    02:01           15:01        57:01   Spleen
  D37           57    02:01   11:01   15:01        35:01   Spleen
  D38           38    02:01   33:01   15:16        57:01   Spleen
  D39           33    02:01   03:01   35:01        51:01   Spleen
  D40           48    02:01   24:02   07:02        15:01   Spleen
  D41           65    02:01   29:02   27:05        44:03   Spleen
  D42           55    02:01   24:02   27:05        35:01   Spleen
  Lymph nodes                                              
  D43           65    02:01   24:02   27:05        35:01   Spleen
  Lymph nodes                                              
  D44           69    02:01   24:02   39:06        40:02   Buffy Pack
  D45           55    03:01   32:01   44:02                Buffy Pack
  D46           22    02:01   68:01   44:02        51:01   Buffy Pack
  D47           29    01:01   24:02   08:01        14:02   Buffy Pack
  D48           31    02:01   03:01   14:02        58:01   Buffy Pack
  D49           30    03:01   24:02   35:03        44:02   Buffy Pack
  D50           41    03:01   11:01   3501         44:02   Buffy Pack
  D51           56    03:01   11:01   07:02        44:03   Buffy Pack
  D52           26    01:01   24:02   08:01        57:01   Buffy Pack
  D53           59    02:01   31:01   15:01 (62)   44:02   Buffy Pack
  D54           35    01:01   03:01   35:01        57:01   Buffy Pack
  D55           69    02:01   32:01   07:02        44:03   Buffy Pack
  D56           ND    03:01           07:02        15:01   Buffy Pack

ND, not determined. HLA subtypes in brackets cannot be ruled out.

Peptides, tetramers and APCs {#sec013}
----------------------------

Universal influenza peptides were purchased from GenScript (Hong Kong) Limited (Central, Hong Kong): A2/M1~58-66~ (GILGFVFTL), A3/NP~265-273~ (ILRGSVAHK), B8/NP~225-233~ (ILKGKFQTA), B18/NP~219-226~ (YERMCNIL), B27/NP~383-391~ (SRYWAIRTR) and B57/NP~199-207~ (RGINDRNFW). Peptide/MHC class I monomers A2/M1~58~ and B27/NP~383~ were generated in-house \[[@ppat.1008714.ref059], [@ppat.1008714.ref065]\] and conjugated at a 8:1 molar ratio with PE-streptavidin (SA) or APC-SA (BD Biosciences, San Jose, CA, USA) to form tetramers. Class I-reduced (C1R) cell lines were kindly provided by Prof. Weisan Chen (La Trobe University, VIC, Australia) (C1R-A\*02:01, C1R-B\*08:01), Prof. James McCluskey (University of Melbourne, VIC, Australia) (C1R-B\*57:01), Prof. Anthony Purcell (Monash University, Australia) (C1R-B\*27:05) and Dr. Nicole Mifsud (Monash University, VIC, Australia) (C1R-A\*03:01, C1R-B\*18:01).

In vitro assays {#sec014}
---------------

Epitope-specific and virus-specific CD8^+^ T cell lines were generated for 10--12 days in RF-10 media (+10 U/ml IL-2) using autologous peptide-pulsed or A/Puerto Rico/8/1934 virus-infected PBMCs as responder cells, as previously described \[[@ppat.1008714.ref015]\]. T cell lines were restimulated with peptide-pulsed HLA-matched C1R cell lines during a 5--6 hour ICS assay, in the presence of GolgiPlug (BD Biosciences) \[[@ppat.1008714.ref038]\]. For the degranulation assay, anti-CD107a AF488 (eBioscience \#53-1079-42) and GolgiStop (BD Biosciences) were also added. Lymphocytes were then surfaced stained with anti-CD3-BV510 (Biolegend \#317332) or anti-CD3 PE-CF594 (BD Biosciences \#562280, anti-CD4 BV650 (BD Horizon \#563875), anti-CD14 APC-H7 (BD Biosciences \#560180), anti-CD19 APC-H7 (BD Biosciences \#560177), anti-CD8 PerCPCy5.5 (BD Biosciences \#565310) and Live/Dead Near-IR (Invitrogen), fixed, then intracellularly stained with anti-IFN-γ v450 (BD Horizon \#560371) and anti-TNF APC (BD Biosciences \#340534) using the Fixation/Permeabilization Solution Kit (BD Cytofix/Cytoperm, BD Biosciences). Samples were acquired on a BD Fortessa (BD Biosciences) and analyzed using Flowjo software version 10 (Treestar, OR, USA). Proliferation kinetics were measured on days d3, d6, d9 and d12 by ICS or tetramer staining to calculate the absolute numbers of epitope-specific cells. For all ICS staining, background staining was subtracted from the no peptide controls.

Ex vivo assays {#sec015}
--------------

PBMCs and spleen MNCs from HLA-A\*02:01^+^/B\*27:05^+^ and HLA-A\*02:01^+^/B\*27:05^-^ individuals were tetramer-stained for 1 hour at room temperature before undergoing dual tetramer-associated magnetic enrichment (TAME), as described \[[@ppat.1008714.ref032]\], using the MACS PE- and APC-MicroBeads and LS columns (Milteny Biotec, Bergisch Galdbach Germany). Lymphocytes were surfaced stained with the above surface antibodies plus anti-CCR7 PECy7 (BD Pharmingen \#557648) and anti-CD45RA FITC (BD Pharmingen \#555488). Samples were acquired on a BD Fortessa or BD FACS Aria III for single-cell sorting and subsequent multiplex-nested RT-PCR for TCR analyses of paired CDR3α and CDR3β regions \[[@ppat.1008714.ref032]\].

Statistical analysis {#sec016}
--------------------

Statistics were performed using GraphPad Prism software (San Diego, CA, USA) to compare between two (Mann-Whitney) or multiple groups (Kruskal-Wallis test, one-way ANOVA), as indicated in the figure legends where *p*\<0.05 was considered statistically significant. PBMCs and spleen MNCs were grouped together for statistical power (except [Fig 2B](#ppat.1008714.g002){ref-type="fig"}).

Supporting information {#sec017}
======================

###### Data source file for Figs [1](#ppat.1008714.g001){ref-type="fig"}--[6](#ppat.1008714.g006){ref-type="fig"}.

Experimental raw data for Figs [1](#ppat.1008714.g001){ref-type="fig"}--[6](#ppat.1008714.g006){ref-type="fig"} are provided in S1 Data.

(XLSX)

###### 

Click here for additional data file.
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Reviewer Comments (if any, and for reference):

Reviewer\'s Responses to Questions

**Part I - Summary**

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer \#1: In this work, the authors studied the immunodominance status of influenza-specific universal CD8+ T-cells in HLA-I heterozygote individuals, which express two or more universal HLAs for Influenza A. The article brings interesting data showing that, while CD8+ T-cell responses directed towards A2/M158 are generally immunodominant, this response is markedly diminished in individuals expressing also the HLA-B\*27:05. The authors show that A2+B27- individuals present highly functional TRBV19/TRAV27 TCRab clonotypes, but that in B27+ persons, A2 cells present increased diversity and increased prevalence of private less functional clonotypes, explaining partially the differential immunodominance of responses. The immunodominance of B27 restricted T-cells has been already demonstrated over the B8 ones (Boon et al., 2002), and, in experimental mice models, the co-expression of B7 and B27 alleles is associated with a B7 immunodominant responses (Akram and Inman, 2013). Although the immunodominance in the context of influenza infection has been already demonstrated in several studies, this article is interesting in showing that HLA-B27 alters the immunodominance hierarchy and functional properties of universal influenza-specific CD8+ T cells, impacting the response of the most prevalent HLA across multiple ethnicities. The understanding of immunodominance in the context of Influenza infection is crucial for the development of T-cells based therapy. The manuscript is clear and well written. The present group has a recognize expertise and many high-quality publications in the field of CD8+ T cell responses in Influenza infection. I have only minor comments.

Reviewer \#2: This is a very well-written manuscript investigating CD8 T cell immunodominance in HLA heterozygotes. The authors have found that A2/M1 CD8 T-cells in non-HLA-B\*27:05 individuals were immunodominant, contained public TCR clonotypes and displayed highly polyfunctional and proliferative capacity. However, in HLA-B\*27:05-expressing donors, A2/M1CD8 T-cells were subdominant, with distinct TCR clonotypes and diminished avidity, proliferation and polyfunctionality. This study will not only help us understand the protective CD8 T cell responses following influenza infection in different individuals, but also have significant impact on the future design of CD8 T cell-based influenza vaccines. The reviewer only has one minor comment regarding the manuscript: if the information is available to the authors, please list age, sex and ethnicity information of the blood donors in a table during revision.

\*\*\*\*\*\*\*\*\*\*

**Part II -- Major Issues: Key Experiments Required for Acceptance**

Please use this section to detail the key new experiments or modifications of existing experiments that should be [absolutely]{.ul} required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a \"Major Revision\" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend \"Reject\".

Reviewer \#1: None

Reviewer \#2: N/A

\*\*\*\*\*\*\*\*\*\*

**Part III -- Minor Issues: Editorial and Data Presentation Modifications**

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer \#1: • In keywords: correct the word "immunodominance";

• In abstract, replace the full stop after "capacity" with a comma;

• In results, correct the text for Figure 2C (line 204). It's indicating Figure 5C;

• About the data Figure 6 and related text , is it correct to conclude that B27 cells are more proliferative than A2 cells based on the numbers of tetramer+ cells and IFN-gamma production upon stimulation??

• Can the authors discuss the fact that A2 and B27 cells (i) present different phenotypes, (ii) althodo not differ in terms of cytotoxins expression?

Reviewer \#2: If the information is available to the authors, please list age, sex and ethnicity information of the blood donors in a table during revision.

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plospathogens/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

[Figure Files:]{.ul}

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, [[https://pacev2.apexcovantage.com](https://pacev2.apexcovantage.com/)]{.ul}. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at [<figures@plos.org>]{.ul}.

[Data Requirements:]{.ul}

Please note that, as a condition of publication, PLOS\' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>.

[Reproducibility:]{.ul}

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see [[http://journals.plos.org/plospathogens/s/submission-guidelines\#loc-materials-and-methods](http://journals.plos.org/plospathogens/s/submission-guidelines)]{.ul}

10.1371/journal.ppat.1008714.r002

Author response to Decision Letter 0

15 Jun 2020

###### 

Submitted filename: Response_to_reviewers PLoS Path.docx

###### 

Click here for additional data file.

10.1371/journal.ppat.1008714.r003

Decision Letter 1

Fernandez-Sesma

Ana

Section Editor

Schultz-Cherry

Stacey

Guest Editor

© 2020 Fernandez-Sesma, Schultz-Cherry

2020

Fernandez-Sesma, Schultz-Cherry

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

18 Jun 2020

Dear A/Prof Kedzierska,

We are pleased to inform you that your manuscript \'HLA-B\*27:05 alters immunodominance hierarchy of universal influenza-specific CD8+ T cells\' has been provisionally accepted for publication in PLOS Pathogens.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Stacey Schultz-Cherry

Guest Editor

PLOS Pathogens

Ana Fernandez-Sesma

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

​[orcid.org/0000-0001-5065-158X](http://orcid.org/0000-0001-5065-158X)

Michael Malim

Editor-in-Chief

PLOS Pathogens

[orcid.org/0000-0002-7699-2064](http://orcid.org/0000-0002-7699-2064)

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Reviewer Comments (if any, and for reference):

10.1371/journal.ppat.1008714.r004

Acceptance letter

Fernandez-Sesma

Ana

Section Editor

Schultz-Cherry

Stacey

Guest Editor

© 2020 Fernandez-Sesma, Schultz-Cherry

2020

Fernandez-Sesma, Schultz-Cherry

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

28 Jul 2020

Dear A/Prof Kedzierska,

We are delighted to inform you that your manuscript, \"HLA-B\*27:05 alters immunodominance hierarchy of universal influenza-specific CD8^+^ T cells,\" has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc\...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

​[orcid.org/0000-0001-5065-158X](http://orcid.org/0000-0001-5065-158X)

Michael Malim

Editor-in-Chief

PLOS Pathogens

[orcid.org/0000-0002-7699-2064](http://orcid.org/0000-0002-7699-2064)

[^1]: The authors have declared that no competing interests exist.

[^2]: Current address: Department of Molecular Biology, University of California, San Diego, California, United States of America

[^3]: Current address: Infection and Immunity Program & Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

[^4]: Current address: Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine, Hannover, Germany.

[^5]: Current address: Department of Immunology and Microbiology, School of Medicine, University of Colorado, Denver, Colorado, United States of America.
